PDF herunterladen
Klin Monbl Augenheilkd 2016; 233(02): 203-219
DOI: 10.1055/s-0033-1358214
Augenheilkunde up2date
Georg Thieme Verlag KG Stuttgart · New York

Unerwünschte Arzneimittelwirkungen in der Augenheilkunde: Update 2015/2016

Adverse Drug Reactions in Ophthalmology – Update 2015/2016
Torsten Schlote
Tagesklinik Ambimed Basel
,
Ulrich Kellner
Zentrum für seltene Netzhauterkrankungen, AugenZentrum Siegburg
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
15. Februar 2016 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Siehe auch:

Unerwünschte Arzneimittelwirkungen in der Augenheilkunde: Update 2015/2016Augenheilkunde up2date 2016; 6(01): 15-29
DOI: 10.1055/s-0041-110754

Unerwünschte Arzneimittelwirkungen (UAW) gehören zum Alltag jedes klinisch tätigen Ophthalmologen. Dies beschränkt sich keineswegs auf die konservative Augenheilkunde, sondern betrifft direkt auch operative Verfahren, wie die Kataraktoperation am Beispiel des intraoperativen Floppy-Iris-Syndroms (IFIS) verdeutlicht.

 

  • Literatur

  • 1 Schlote T, Kellner U. Nebenwirkungen von Medikamenten am Auge. Klimo-Refresher. Klin Monatsbl Augenheilkd 2009; 226: R173-R186
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 2 Schlote T, Kellner U. Unerwünschte Arzneimittelwirkungen in der Augenheilkunde – Update 2011/12. Klin Monatsbl Augenheilkd 2012; 229: 275-290
    PubMedGoogle Scholar
  • 3 Vuori ML, Kaila T, Iisalo E et al. Systemic absorption and anticholinergic activity of topically applied tropicamide. J Ocul Pharmacol 1994; 10: 431-437
    CrossrefPubMedGoogle Scholar
  • 4 Bersani FS, Imperatori C, Prilutskaya M et al. Injecting eye-drops: a mini-review on the non-clinical use of tropicamide. Hum Psychopharmacol 2015; 30: 262-264
    CrossrefPubMedGoogle Scholar
  • 5 Raison-Peyron N, Du Thanh A, Demoly P et al. Long-lasting allergic contact blepharoconjunctivitis to phenylephrine eyedrops. Allergy 2009; 64: 657-658
    CrossrefPubMedGoogle Scholar
  • 6 Stavert B, McGuinness MB, Heper CA et al. Cardiovascular adverse effects of phenylephrine eyedrops: A systematic review and meta-analysis. JAMA Ophthalmol 2015; 133: 647-652
    CrossrefPubMedGoogle Scholar
  • 7 Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005; 31: 664-673
    CrossrefPubMedGoogle Scholar
  • 8 Chang DF, Campbell JR, Colin J et al. Prospective masked comparison of intraoperative floppy iris syndrome severity with tamsulosin versus alfuzosin. Ophthalmology 2014; 121: 829-834
    CrossrefPubMedGoogle Scholar
  • 9 Casuccio A, Cillino G, Pavone C et al. Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome. J Cataract Refract Surg 2011; 37: 1447-1454
    CrossrefPubMedGoogle Scholar
  • 10 Schmitz K, Maier M, Clemens CR et al. Zuverlässigkeit und Sicherheit von intravitrealen Ozurdex-Injektionen. Die ZERO-Studie. Ophthalmologe 2014; 111: 44-52 DOI: 10.1007/s00347-012-2737-2.
    CrossrefPubMedGoogle Scholar
  • 11 Mazzarella S, Mateo C, Freixes S et al. Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex®) on intraocular pressure in patients with macular edema. Ophthalmic Res 2015; 54: 143-149
    CrossrefPubMedGoogle Scholar
  • 12 Mathalone N, Arodi-Golan A, Sar S et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012; 250: 1435-1440 DOI: 10.1007/s00417-012-1981-0.
    CrossrefPubMedGoogle Scholar
  • 13 Tseng JJ, Vance SK, Della Torre KE et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2012; 21: 241-247 DOI: 10.1097/IJG.0b013e31820d7d19.
    CrossrefPubMedGoogle Scholar
  • 14 Dedania VS, Bakri SJ. Sustained elevation of intraocular pressure after intravitreal anti-VEGF agents: What is the evidence?. Retina 2015; 35: 841-858
    CrossrefPubMedGoogle Scholar
  • 15 Ricca AM, Morshedi RG, Wirostko BM. High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism. J Ocul Pharmacol Ther 2015; 31: 2-10
    CrossrefPubMedGoogle Scholar
  • 16 Narayanaswamy A, Neog A, Baskaran M et al. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol 2007; 55: 127-131
    CrossrefPubMedGoogle Scholar
  • 17 Marmor MF, Kellner U, Lai TY et al. 2016 Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2016; [in press]
    PubMedGoogle Scholar
  • 18 Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014; 132: 1453-1460
    CrossrefPubMedGoogle Scholar
  • 19 Lee Y, Vinayagamoorthy N, Han K et al. Polymorphisms of cytochrome P450 2D6 are associated with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol 2015; Aug 28. DOI: 10.1002/art.39402. [Epub ahead of print]
    PubMedGoogle Scholar
  • 20 Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 2015; 122: 110-116
    CrossrefPubMedGoogle Scholar
  • 21 Leung LS, Neal JW, Wakelee HA et al. Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy. Am J Ophthalmol 2015; 160: 799-805
    CrossrefPubMedGoogle Scholar
  • 22 Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol 2014; 132: 1105-1112
    CrossrefPubMedGoogle Scholar
  • 23 Kellner S, Weinitz S, Farmand G et al. Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol 2014; 98: 200-206
    CrossrefPubMedGoogle Scholar
  • 24 Liu L, Cuthbertson F. Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis. Case Rep Med 2012; 2012: 134636 DOI: 10.1155/2012/134636.
    PubMedGoogle Scholar
  • 25 Nolan R, Gelfand JM, Green AJ. Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology 2013; 80: 139-144
    CrossrefPubMedGoogle Scholar
  • 26 Zarbin MA, Jampol LM, Jager RD et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology 2013; 120: 1432-1439
    CrossrefPubMedGoogle Scholar
  • 27 Georgakopoulos CD, Makri OE, Vasilakis P et al. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy. Clin Exp Optom 2012; 95: 233-236
    CrossrefPubMedGoogle Scholar
  • 28 Ehlers JP, Rayess H, Steinle N. Topical dorzolamide therapy for taxane-related macular oedema. Eye (Lond) 2013; 27: 102-104
    CrossrefPubMedGoogle Scholar
  • 29 Crabtree DV, Ojima I, Geng X et al. Tubulins in the primate retina: evidence that xanthophylls may be endogenous ligands for the paclitaxel-binding site. Bioorg Med Chem 2001; 9: 1967-1976
    CrossrefPubMedGoogle Scholar
  • 30 Splinter MY. Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults. J Cent Nerv Syst Dis 2013; 5: 31-41
    PubMedGoogle Scholar
  • 31 Garin Shkolnik T, Feuerman H, Didkovsky E et al. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. JAMA Dermatol 2014; 150: 984-989
    CrossrefPubMedGoogle Scholar
  • 32 Kawazoe Y, Sugita S, Yamada Y et al. Psoriasis triggered by infliximab in a patient with Behçetʼs disease. Jpn J Ophthalmol 2013; 57: 95-97
    CrossrefPubMedGoogle Scholar
  • 33 Tarkiainen M, Tynjälä P, Vähäsalo P et al. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatology (Oxford) 2015; 54: 1170-1176
    CrossrefPubMedGoogle Scholar
  • 34 Zamvar U, Dhillon B. Postoperative IOP prophylaxis practice following uncomplicated cataract surgery: a UK-wide consultant survey. BMC Ophthalmol 2005; 5: 24
    CrossrefPubMedGoogle Scholar
  • 35 Gallerani M, Manzoli N, Fellin R et al. Anaphylactic shock and acute pulmonary edema after a single oral dose of acetazolamide. Am J Emerg Med 2002; 20: 371-372
    CrossrefPubMedGoogle Scholar
  • 36 Zimmermann S, Achenbach S, Wolf M et al. Recurrent shock and pulmonary edema due to acetazolamide medication after cataract surgery. Heart Lung 2014; 43: 124-126
    CrossrefPubMedGoogle Scholar
  • 37 Choksi V, Hughes M, Selwa L et al. Transient neurologic deficit after acetazolamide challenge for computed tomography perfusion imaging. J Comput Assist Tomogr 2005; 29: 278-280
    CrossrefPubMedGoogle Scholar
  • 38 Parthasarathi S, Myint K, Singh G et al. Bilateral acetazolamide-induced choroidal effusion following cataract surgery. Eye (Lond) 2007; 21: 870-872
    CrossrefPubMedGoogle Scholar
  • 39 Lachkar Y, Bouassida W. Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol 2007; 18: 129-133
    CrossrefPubMedGoogle Scholar
  • 40 Mancino R, Varesi C, Cerulli A et al. Acute bilateral angle-closure glaucoma and choroidal effusion associated with acetazolamide administration after cataract surgery. J Cataract Refract Surg 2011; 37: 415-417
    CrossrefPubMedGoogle Scholar
  • 41 Malagola R, Arrico L, Giannotti R et al. Acetazolamide-induced cilio-choroidal effusion after cataract surgery: unusual posterior involvement. Drug Des Devel Ther 2013; 7: 33-36
    PubMedGoogle Scholar
  • 42 De Rojas V, González-López F, Baviera J. Acetazolamide-induced bilateral choroidal effusion following insertion of a phakic implantable collamer lens. J Refract Surg 2013; 29: 570-572
    CrossrefPubMedGoogle Scholar